1. Pharmacological action
2. Product form Bonviva
3. Indications Bonviva
7. Side effects
8. Overdose Bonviva
Bonviva - ibandronic acid drug that inhibits bone resorption in osteoporosis in postmenopausal women.
Ibandronic acid is a highly nitrogen-containing bisphosphonate that inhibits bone resorption and osteoclast activity.When receiving Bonviva and analogues, ibandronic acid prevents bone destruction caused by cessation of gonadal function, retinoids, tumors and tumor extracts.
In conducting research on young, growing rats, it was found that ibandronic acid inhibits endogenous bone resorption, resulting in animals maintained a higher bone mass, compared with individuals in the control group.Thus mineralization of bones and osteoclasts pool refill process is not disturbed even when the dose exceeded more than 5000 times.Ibandronic acid acts selectively on bone due to its hi
Thus Bonviva preparation of instructions slows bone resorption without exerting a direct effect on bone formation.When receiving the drug in women during menopause, reduces the increase rate of bone turnover to the level of reproductive age, which leads to a progressive increase in bone mass, reducing the splitting of bone collagen in urine and serum, a decrease in the risk of fractures.
characteristic that, in the opinion on the Bonviva after stopping treatment is an increase in the level of bone resorption, which is characteristic of post-menopausal osteoporosis.
high activity and therapeutic range ibandronic acid provides flexibility and intermittent dosing destination Bonviva analogs and for a long period without treatment at low doses.
histological analysis samples of bone taken from women in menopause 2 and 3 years after the treatment, showed that normal bone tissue retains characteristics and shows no signs of mineralization disorders.At the same throughout the life of the drug is stored prevention of fractures, signs of leveling effect over time are absent.Possibly carcinogenic and genotoxic activity have been identified.
After oral administration of ibandronic acid is rapidly absorbed in the upper gastrointestinal tract.Eating and drinking beverages other than water, at the same time or within one hour after ingestion decreases its bioavailability.
About half the total amount of introduced ibandonovoy acid circulating in the blood, the bone tissue penetrates and it accumulates in the remaining part appears unchanged in the urine.Unabsorbed drug is excreted in the feces.It is estimated that ibandronic acid is metabolized.Thus pharmacokinetic parameters studied drug does not vary depending on the age of the patient, in the absence of serious kidney problems in old age.
in accordance with the instructions, Bonviva is available in tablets, film-coated, or as a solution for intravenous administration.
In accordance with the instructions for Bonviva, indicating the reception of the drug is postmenopausal osteoporosis with a view to preventing fractures.
Bonviva and analogues are contraindicated in hypocalcemia, esophageal lesions, which lead to delay emptying (stricture, ahaliziya), severe renal impairment.The drug is not prescribed if it is impossible to be in standing or sitting for an hour after taking the pill, as well as children under 18 years of age and hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption.Also according to the instructions, Bonvian can not be taken in case of hypersensitivity to the drug.
With care, you can take the medicine with active pathological processes localized in the upper gastrointestinal tract, such as ulcers, gastritis, duodenitis.
drug is taken orally at a dose of 150 mg (1 tablet) 1 time per month, while it is desirable to take it in the same day of each month.Means for taking up to 60 minutes in the first day the meal, liquid or other drugs and food additives.Exception - water.The tablet should be swallowed whole with a glass of clean water while sitting or standing, and can not go to bed for an hour after taking the drug.
This is not to drink mineral water with a high calcium content.Tablets should not be chewed or sucked out of the risk of oesophageal ulceration.
When planning the drug was passed and before the planned admission is more than a week, you should immediately take 1 tablet Bonviva and continue taking the drug carried out in accordance with the previously established schedule.If, however, until the next reception have less than a week, you should wait until the next dose and continue to take the medicine according to the schedule.It is not allowed to take more than 1 tablet per week of the drug.
If abnormal liver function, mild to moderate impaired renal function and for elderly patients the dose is not adjusted.
solution for intravenous administration should be administered only by specialists.
Do not take Bonviva and analogues during pregnancy and lactation.
Note that foods and food supplements, antacids and medicines, which include calcium and other polyvalent cations (magnesium, aluminum, iron), including milk and solid food, can hinder the process of absorption of the drug, so theirit is recommended to use no earlier than an hour after taking Bonviva tablets.
In the opinion of Bonviva on possible development of inflammatory diseases of the eye, which are unable to be cured only after discontinuation of the drug.Occasionally there have been cases of osteonecrosis of the jaw.
In addition, the drug Bonviva and analogues can lead to nausea, vomiting, diarrhea, gastritis, dyspepsia, headache, dizziness, rash, urticaria, general weakness, back pain, muscle spasms, sleep disorders, depression, fatigue.In a review on the Bonviva is indicated that after the first dose of the drug could experience mild to moderate flu-like symptoms.
Excess doses at reviews on Bonviva can cause dyspepsia, esophagitis, gastritis, ulcer upper gastrointestinal tract.
specific information about the treatment of these symptoms is not.In accordance with the instructions in Bonviva, ibandronic acid, is associated with milk or antacids.At the same time due to the possibility of esophageal irritation is not recommended to induce vomiting and the need to maintain the straightened position of "standing."
Product description posted on this page is a supplement and a simplified version of the official version of the annotations to the drug.The information is provided for informational purposes only and is not a guide to self-medication.Before using the product you should consult with a specialist and to get acquainted with the instructions approved by the manufacturer.
Contents: 1. Instruction Neyromultivitu 2. Analogs Neyromultivita Neyromultivit is a complex preparation containing in its com...
Contents: 1. Analogs neuromidin 2. Pharmacological action 3. Instruction neuromidin - indications for use 4. Dosing neuromidi...
Contents: 1. Pharmacological action 2. Instruction Neyrodiklovitu - indications for use 3. Dosing Neyrodiklovita 4. Contraind...